The Pharmacovigilance Market is expected to reach USD 12.03 Bn by 2031 and was valued at USD 7.05 Bn in 2023 and simultaneously grow at a CAGR of 6.9% over the forecast period of 2024-2031.
The research and practises involved in the identification, evaluation, comprehension, and prevention of side effects or any other drug-related issues connected to the use of drugs are known as pharmacovigilance. After a drug has been licenced and is on the market, it is vital to ensure its safety and effectiveness.
Get more information on Pharmacovigilance Market - Request Free Sample Report
Pharmacovigilance systems gather, examine, and assess information on adverse drug reactions (ADRs) and other drug-related issues as a means of monitoring medication safety. This aids in recognising potential safety issues, such as uncommon or long-term consequences, and in taking the necessary precautions to reduce hazards.
Pharmacovigilance seeks to spot growing risks or potential safety signals related to drug use. This entails tracking reported adverse events continuously and analysing data from a range of sources, including literature, spontaneous reporting systems, clinical trials, and empirical data. Pharmacovigilance is essential in determining how the advantages and disadvantages of drugs balance out. This entails assessing the information that is currently available regarding the efficacy and safety of medications and coming to wise decisions regarding regulatory actions, labelling revisions, or adjustments to drug usage advice.
Driver
Unwanted or unpleasant side effects that develop as a result of taking medication are referred to as adverse drug responses. ADRs might be moderate and manageable or severe and potentially fatal. Pharmacovigilance seeks to recognise and comprehend ADRs, evaluate their frequency and seriousness, and take the necessary steps to reduce their incidence and adverse effects on patient health.
Opportunity
The constant evaluation and assessment of the benefit-risk profiles of drugs depend heavily on pharmacovigilance. By balancing a drug's therapeutic advantages and potential hazards, it aids regulatory bodies, medical practitioners, and patients in making wise decisions. Pharmacovigilance permits the optimisation of pharmacological therapy and the minimization of risks by constantly observing and examining safety data.
Restrain
Activities related to pharmacovigilance demand sufficient resources, such as skilled employees, information systems, and financial backing. However, a lack of funding, particularly in low- and middle-income nations, might make it difficult to put pharmacovigilance systems into place effectively. The effective operation of pharmacovigilance programmes can be hampered by inadequate infrastructure, a lack of financing, and restricted capability for data collecting, analysis, and communication.
Challenge
The underreporting of adverse events by medical personnel and patients is one of the major difficulties in pharmacovigilance. Due to issues like lack of knowledge of reporting systems, time restraints, the belief that reporting is a time-consuming process, fear of liability, or a lack of understanding of the need of adverse event reporting, many adverse occurrences go unreported. Underreporting can lead to inaccurate safety data and make it more difficult to identify new risks.
The availability and quality of medications in the affected areas can be impacted by the war, which can disrupt the supply networks for pharmaceuticals. By changing drug usage habits, introducing new treatments with potentially differing safety profiles, or encouraging the use of fake or subpar medications, which might raise the likelihood of adverse events, these factors can have an impact on pharmacovigilance.
Due to the conflict, patients and healthcare workers may be moved. This can make it difficult to maintain continuity of care, lose medical records, and track and monitor adverse events linked to particular medications or patient populations.
Impact of Recession :
Budgets for research and development are susceptible to the effects of a recession in the pharmaceutical sector. It's possible that businesses will postpone or scale back their spending on safety or new drug research, which might restrict access to cutting-edge medicines. Due to potential changes in risk profiles brought on by the introduction of new medications, this may have an impact on the scope and relevance of pharmacovigilance operations. Hospitals, clinics, and laboratories may all experience stress as a result of economic downturns. The efficiency with which healthcare facilities can gather, analyse, and report pharmacovigilance data might be affected by a lack of resources and financing. The overall efficiency of pharmacovigilance systems may be hampered as a result of the safety information's lower quality and availability.
By product Life Cycle
Pre-Clinical
Phase I
Phase II
Phase III
Phase IV
By Service Provider Outlook
In-house
Contract Outsourcing
By Type Outlook
Spontaneous reporting
Intensified ADR Reporting
EHE mining
Process Flow Outlook
Case Data management
Signal Detection
Risk Management System
Therapeutic Outlook
Oncology
Neurology
Cardiology
Respiratory systems
Others
End Use Outlook
Pharmaceuticals
Medical Device manufacturers
Others
Need any customization research on Pharmacovigilance Market - Enquiry Now
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Regional Analysis :
North America is the region with the highest share there are several factors which contribute to this growth, the major ones are that pharmacovigilance frameworks are in place at regulatory agencies including the U.S. Food and Drug Administration (FDA) and Health Canada. These locations have established methods for signal identification and risk management, well-defined reporting systems, and post-marketing surveillance programmes. In order to ensure patient safety, regulatory organisations, medical experts, and industry stakeholders must work together.
Europe is the region with the second largest share because under the EU's pharmacovigilance legislation, all European nations, including those that make up the EU, have standardised their pharmacovigilance laws. Pharmacovigilance actions are coordinated at the European level by the European Medicines Agency (EMA), with local implementation being the responsibility of individual member states. The use of a centralised reporting database (EudraVigilance) and cross-border sharing of safety data are both stressed by the European pharmacovigilance system.
The major key players are Accenture, IQVIA, Cognizant, IBM Corp, Wipro Ltd, BioClinica Inc, Capgemini, ArisGlobal, ITClinical. ClinChoice, United BioSource LLC, Parexel International Corp., TAKE Solutions Ltd., ICON plc., Laboratory Corporation of America Holdings and Other Players.
Accenture: The collaboration between the UCB and Accenture in order to accelerate data processing and help improve patient safety.
IBM: The collaboration between Celgene and IBM Watson Health Forge which is designed to transform patient safety monitoring.
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.05 Bn |
| Market Size by 2031 | US$ 12.03 Bn |
| CAGR | CAGR of 6.9% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By product Life Cycle • By Service Provider Outlook • By Type Outlook • By Process Flow Outlook • By Therapeutic Outlook • By End Use Outlook |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Accenture, IQVIA, Cognizant, IBM Corp, Wipro Ltd, BioClinica Inc, Capgemini, ArisGlobal, ITClinical. ClinChoice, United BioSource LLC, Parexel International Corp., TAKE Solutions Ltd., ICON plc., Laboratory Corporation of America Holdings |
| Key Drivers | • Unwanted or unpleasant side effects that develop as a result of taking medication are referred to as adverse drug responses |
| Market Restraints | • Activities related to pharmacovigilance demand sufficient resources, such as skilled employees, information systems, and financial backing. |
Ans: The Pharmacovigilance Market is expected to grow at a CAGR of 6.8 %.
Ans: The Pharmacovigilance Market size is estimated to reach USD 11.17 Bn by 2030.
Ans: The North American region held the largest market share of 30 % in 2022 and will continue to dominate the market.
Ans: The constant evaluation and assessment of the benefit-risk profiles of drugs depend heavily on pharmacovigilance
Ans: Pharmacovigilance seeks to recognise and comprehend ADRs, evaluate their frequency and seriousness, and take the necessary steps to reduce their incidence and adverse effects on patient health.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4 Impact Of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Pharmacovigilance Market Segmentation, By Product Life Cycle
8.1 Pre-Clinical
8.2 Phase I
8.3 Phase II
8.4 Phase III
8.5 Phase IV
9. Pharmacovigilance Market Segmentation, By Service Provider Outlook
9.1 In-house
9.2 Contract Outsourcing
10. Pharmacovigilance Market Segmentation, By Process Flow Outlook
10.1 Case Data management
10.2 Signal Detection
10.3 Risk Management System
11. Pharmacovigilance Market Segmentation, By Therapeutic Outlook
11.1 Oncology
11.2 Neurology
11.3 Cardiology
11.4 Respiratory systems
11.5 Others
12. Pharmacovigilance Market Segmentation, By End Use Outlook
12.1 Pharmaceuticals
12.2 Medical Device manufacturers
12.3 Others
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 North America Pharmacovigilance Market By Country
13.2.2 North America Pharmacovigilance Market By Product Life Cycle
13.2.3 North America Pharmacovigilance Market By Service Provider Outlook
13.2.4 North America Pharmacovigilance Market By Process Flow Outlook
13.2.5 North America Pharmacovigilance Market By Therapeutic Outlook
13.2.6 North America Pharmacovigilance Market By End Use Outlook
13.2.7 USA
13.2.7.1 USA Pharmacovigilance Market By Product Life Cycle
13.2.7.2 USA Pharmacovigilance Market By Service Provider Outlook
13.2.7.3 USA Pharmacovigilance Market By Process Flow Outlook
13.2.7.4 USA Pharmacovigilance Market By Therapeutic Outlook
13.2.7.5 USA Pharmacovigilance Market By End Use Outlook
13.2.8 Canada
13.2.8.1 Canada Pharmacovigilance Market By Product Life Cycle
13.2.8.2 Canada Pharmacovigilance Market By Service Provider Outlook
13.2.8.3 Canada Pharmacovigilance Market By Process Flow Outlook
13.2.8.4 Canada Pharmacovigilance Market By Therapeutic Outlook
13.2.8.5 Canada Pharmacovigilance Market By End Use Outlook
13.2.9 Mexico
13.2.9.1 Mexico Pharmacovigilance Market By Product Life Cycle
13.2.9.2 Mexico Pharmacovigilance Market By Service Provider Outlook
13.2.9.3 Mexico Pharmacovigilance Market By Process Flow Outlook
13.2.9.4 Mexico Pharmacovigilance Market By Therapeutic Outlook
13.2.9.5 Mexico Pharmacovigilance Market By End Use Outlook
13.3 Europe
13.3.1 Eastern Europe
13.3.1.1 Eastern Europe Pharmacovigilance Market By Country
13.3.1.2 Eastern Europe Pharmacovigilance Market By Product Life Cycle
13.3.1.3 Eastern Europe Pharmacovigilance Market By Service Provider Outlook
13.3.1.4 Eastern Europe Pharmacovigilance Market By Process Flow Outlook
13.3.1.5 Eastern Europe Pharmacovigilance Market By Therapeutic Outlook
13.3.1.6 Eastern Europe Pharmacovigilance Market By End Use Outlook
13.3.1.7 Poland
13.3.1.7.1 Poland Pharmacovigilance Market By Product Life Cycle
13.3.1.7.2 Poland Pharmacovigilance Market By Service Provider Outlook
13.3.1.7.3 Poland Pharmacovigilance Market By Process Flow Outlook
13.3.1.7.4 Poland Pharmacovigilance Market By Therapeutic Outlook
13.3.1.7.5 Poland Pharmacovigilance Market By End Use Outlook
13.3.1.8 Romania
13.3.1.8.1 Romania Pharmacovigilance Market By Product Life Cycle
13.3.1.8.2 Romania Pharmacovigilance Market By Service Provider Outlook
13.3.1.8.3 Romania Pharmacovigilance Market By Process Flow Outlook
13.3.1.8.4 Romania Pharmacovigilance Market By Therapeutic Outlook
13.3.1.8.5 Romania Pharmacovigilance Market By End Use Outlook
13.3.1.9 Hungary
13.3.1.9.1 Hungary Pharmacovigilance Market By Product Life Cycle
13.3.1.9.2 Hungary Pharmacovigilance Market By Service Provider Outlook
13.3.1.9.3 Hungary Pharmacovigilance Market By Process Flow Outlook
13.3.1.9.4 Hungary Pharmacovigilance Market By Therapeutic Outlook
13.3.1.9.5 Hungary Pharmacovigilance Market By End Use Outlook
13.3.1.10 Turkey
13.3.1.10.1 Turkey Pharmacovigilance Market By Product Life Cycle
13.3.1.10.2 Turkey Pharmacovigilance Market By Service Provider Outlook
13.3.1.10.3 Turkey Pharmacovigilance Market By Process Flow Outlook
13.3.1.10.4 Turkey Pharmacovigilance Market By Therapeutic Outlook
13.3.1.10.5 Turkey Pharmacovigilance Market By End Use Outlook
13.3.1.11 Rest of Eastern Europe
13.3.1.11.1 Rest of Eastern Europe Pharmacovigilance Market By Product Life Cycle
13.3.1.11.2 Rest of Eastern Europe Pharmacovigilance Market By Service Provider Outlook
13.3.1.11.3 Rest of Eastern Europe Pharmacovigilance Market By Process Flow Outlook
13.3.1.11.4 Rest of Eastern Europe Pharmacovigilance Market By Therapeutic Outlook
13.3.1.11.5 Rest of Eastern Europe Pharmacovigilance Market By End Use Outlook
13.3.2 Western Europe
13.3.2.1 Western Europe Pharmacovigilance Market By Country
13.3.2.2 Western Europe Pharmacovigilance Market By Product Life Cycle
13.3.2.3 Western Europe Pharmacovigilance Market By Service Provider Outlook
13.3.2.4 Western Europe Pharmacovigilance Market By Process Flow Outlook
13.3.2.5 Western Europe Pharmacovigilance Market By Therapeutic Outlook
13.3.2.6 Western Europe Pharmacovigilance Market By End Use Outlook
13.3.2.7 Germany
13.3.2.7.1 Germany Pharmacovigilance Market By Product Life Cycle
13.3.2.7.2 Germany Pharmacovigilance Market By Service Provider Outlook
13.3.2.7.3 Germany Pharmacovigilance Market By Process Flow Outlook
13.3.2.7.4 Germany Pharmacovigilance Market By Therapeutic Outlook
13.3.2.7.5 Germany Pharmacovigilance Market By End Use Outlook
13.3.2.8 France
13.3.2.8.1 France Pharmacovigilance Market By Product Life Cycle
13.3.2.8.2 France Pharmacovigilance Market By Service Provider Outlook
13.3.2.8.3 France Pharmacovigilance Market By Process Flow Outlook
13.3.2.8.4 France Pharmacovigilance Market By Therapeutic Outlook
13.3.2.8.5 France Pharmacovigilance Market By End Use Outlook
13.3.2.9 UK
13.3.2.9.1 UK Pharmacovigilance Market By Product Life Cycle
13.3.2.9.2 UK Pharmacovigilance Market By Service Provider Outlook
13.3.2.9.3 UK Pharmacovigilance Market By Process Flow Outlook
13.3.2.9.4 UK Pharmacovigilance Market By Therapeutic Outlook
13.3.2.9.5 UK Pharmacovigilance Market By End Use Outlook
13.3.2.10 Italy
13.3.2.10.1 Italy Pharmacovigilance Market By Product Life Cycle
13.3.2.10.2 Italy Pharmacovigilance Market By Service Provider Outlook
13.3.2.10.3 Italy Pharmacovigilance Market By Process Flow Outlook
13.3.2.10.4 Italy Pharmacovigilance Market By Therapeutic Outlook
13.3.2.10.5 Italy Pharmacovigilance Market By End Use Outlook
13.3.2.11 Spain
13.3.2.11.1 Spain Pharmacovigilance Market By Product Life Cycle
13.3.2.11.2 Spain Pharmacovigilance Market By Service Provider Outlook
13.3.2.11.3 Spain Pharmacovigilance Market By Process Flow Outlook
13.3.2.11.4 Spain Pharmacovigilance Market By Therapeutic Outlook
13.3.2.11.5 Spain Pharmacovigilance Market By End Use Outlook
13.3.2.12 The Netherlands
13.3.2.12.1 Netherlands Pharmacovigilance Market By Product Life Cycle
13.3.2.12.2 Netherlands Pharmacovigilance Market By Service Provider Outlook
13.3.2.12.3 Netherlands Pharmacovigilance Market By Process Flow Outlook
13.3.2.12.4 Netherlands Pharmacovigilance Market By Therapeutic Outlook
13.3.2.12.5 Netherlands Pharmacovigilance Market By End Use Outlook
13.3.2.13 Switzerland
13.3.2.13.1 Switzerland Pharmacovigilance Market By Product Life Cycle
13.3.2.13.2 Switzerland Pharmacovigilance Market By Service Provider Outlook
13.3.2.13.3 Switzerland Pharmacovigilance Market By Process Flow Outlook
13.3.2.13.4 Switzerland Pharmacovigilance Market By Therapeutic Outlook
13.3.2.13.5 Switzerland Pharmacovigilance Market By End Use Outlook
13.3.2.14 Austria
13.3.2.14.1 Austria Pharmacovigilance Market By Product Life Cycle
13.3.2.14.2 Austria Pharmacovigilance Market By Service Provider Outlook
13.3.2.14.3 Austria Pharmacovigilance Market By Process Flow Outlook
13.3.2.14.4 Austria Pharmacovigilance Market By Therapeutic Outlook
13.3.2.14.5 Austria Pharmacovigilance Market By End Use Outlook
13.3.2.15 Rest of Western Europe
13.3.2.15.1 Rest of Western Europe Pharmacovigilance Market By Product Life Cycle
13.3.2.15.2 Rest of Western Europe Pharmacovigilance Market By Service Provider Outlook
13.3.2.15.3 Rest of Western Europe Pharmacovigilance Market By Process Flow Outlook
13.3.2.15.4 Rest of Western Europe Pharmacovigilance Market By Therapeutic Outlook
13.3.2.15.5 Rest of Western Europe Pharmacovigilance Market By End Use Outlook
13.4 Asia-Pacific
13.4.1 Asia Pacific Pharmacovigilance Market By Country
13.4.2 Asia Pacific Pharmacovigilance Market By Product Life Cycle
13.4.3 Asia Pacific Pharmacovigilance Market By Service Provider Outlook
13.4.4 Asia Pacific Pharmacovigilance Market By Process Flow Outlook
13.4.5 Asia Pacific Pharmacovigilance Market By Therapeutic Outlook
13.4.6 Asia Pacific Pharmacovigilance Market By End Use Outlook
13.4.7 China
13.4.7.1 China Pharmacovigilance Market By Product Life Cycle
13.4.7.2 China Pharmacovigilance Market By Service Provider Outlook
13.4.7.3 China Pharmacovigilance Market By Process Flow Outlook
13.4.7.4 China Pharmacovigilance Market By Therapeutic Outlook
13.4.7.5 China Pharmacovigilance Market By End Use Outlook
13.4.8 India
13.4.8.1 India Pharmacovigilance Market By Product Life Cycle
13.4.8.2 India Pharmacovigilance Market By Service Provider Outlook
13.4.8.3 India Pharmacovigilance Market By Process Flow Outlook
13.4.8.4 India Pharmacovigilance Market By Therapeutic Outlook
13.4.8.5 India Pharmacovigilance Market By End Use Outlook
13.4.9 Japan
13.4.9.1 Japan Pharmacovigilance Market By Product Life Cycle
13.4.9.2 Japan Pharmacovigilance Market By Service Provider Outlook
13.4.9.3 Japan Pharmacovigilance Market By Process Flow Outlook
13.4.9.4 Japan Pharmacovigilance Market By Therapeutic Outlook
13.4.9.5 Japan Pharmacovigilance Market By End Use Outlook
13.4.10 South Korea
13.4.10.1 South Korea Pharmacovigilance Market By Product Life Cycle
13.4.10.2 South Korea Pharmacovigilance Market By Service Provider Outlook
13.4.10.3 South Korea Pharmacovigilance Market By Process Flow Outlook
13.4.10.4 South Korea Pharmacovigilance Market By Therapeutic Outlook
13.4.10.5 South Korea Pharmacovigilance Market By End Use Outlook
13.4.11 Vietnam
13.4.11.1 Vietnam Pharmacovigilance Market By Product Life Cycle
13.4.11.2 Vietnam Pharmacovigilance Market By Service Provider Outlook
13.4.11.3 Vietnam Pharmacovigilance Market By Process Flow Outlook
13.4.11.4 Vietnam Pharmacovigilance Market By Therapeutic Outlook
13.4.11.5 Vietnam Pharmacovigilance Market By End Use Outlook
13.4.12 Singapore
13.4.12.1 Singapore Pharmacovigilance Market By Product Life Cycle
13.4.12.2 Singapore Pharmacovigilance Market By Service Provider Outlook
13.4.12.3 Singapore Pharmacovigilance Market By Process Flow Outlook
13.4.12.4 Singapore Pharmacovigilance Market By Therapeutic Outlook
13.4.12.5 Singapore Pharmacovigilance Market By End Use Outlook
13.4.13 Australia
13.4.13.1 Australia Pharmacovigilance Market By Product Life Cycle
13.4.13.2 Australia Pharmacovigilance Market By Service Provider Outlook
13.4.13.3 Australia Pharmacovigilance Market By Process Flow Outlook
13.4.13.4 Australia Pharmacovigilance Market By Therapeutic Outlook
13.4.13.5 Australia Pharmacovigilance Market By End Use Outlook
13.4.14 Rest of Asia-Pacific
13.4.14.1 APAC Pharmacovigilance Market By Product Life Cycle
13.4.14.2 APAC Pharmacovigilance Market By Service Provider Outlook
13.4.14.3 APAC Pharmacovigilance Market By Process Flow Outlook
13.4.14.4 APAC Pharmacovigilance Market By Therapeutic Outlook
13.4.14.5 APAC Pharmacovigilance Market By End Use Outlook
13.5 The Middle East & Africa
13.5.1 Middle East
13.5.1.1 Middle East Pharmacovigilance Market By country
13.5.1.2 Middle East Pharmacovigilance Market By Product Life Cycle
13.5.1.3 Middle East Pharmacovigilance Market By Service Provider Outlook
13.5.1.4 Middle East Pharmacovigilance Market By Process Flow Outlook
13.5.1.5 Middle East Pharmacovigilance Market By Therapeutic Outlook
13.5.1.6 Middle East Pharmacovigilance Market By End Use Outlook
13.5.1.7 UAE
13.5.1.7.1 UAE Pharmacovigilance Market By Product Life Cycle
13.5.1.7.2 UAE Pharmacovigilance Market By Service Provider Outlook
13.5.1.7.3 UAE Pharmacovigilance Market By Process Flow Outlook
13.5.1.7.4 UAE Pharmacovigilance Market By Therapeutic Outlook
13.5.1.7.5 UAE Pharmacovigilance Market By End Use Outlook
13.5.1.8 Egypt
13.5.1.8.1 Egypt Pharmacovigilance Market By Product Life Cycle
13.5.1.8.2 Egypt Pharmacovigilance Market By Service Provider Outlook
13.5.1.8.3 Egypt Pharmacovigilance Market By Process Flow Outlook
13.5.1.8.4 Egypt Pharmacovigilance Market By Therapeutic Outlook
13.5.1.8.5 Egypt Pharmacovigilance Market By End Use Outlook
13.5.1.9 Saudi Arabia
13.5.1.9.1 Saudi Arabia Pharmacovigilance Market By Product Life Cycle
13.5.1.9.2 Saudi Arabia Pharmacovigilance Market By Service Provider Outlook
13.5.1.9.3 Saudi Arabia Pharmacovigilance Market By Process Flow Outlook
13.5.1.9.4 Saudi Arabia Pharmacovigilance Market By Therapeutic Outlook
13.5.1.9.5 Saudi Arabia Pharmacovigilance Market By End Use Outlook
13.5.1.10 Qatar
13.5.1.10.1 Qatar Pharmacovigilance Market By Product Life Cycle
13.5.1.10.2 Qatar Pharmacovigilance Market By Service Provider Outlook
13.5.1.10.3 Qatar Pharmacovigilance Market By Process Flow Outlook
13.5.1.10.4 Qatar Pharmacovigilance Market By Therapeutic Outlook
13.5.1.10.5 Qatar Pharmacovigilance Market By End Use Outlook
13.5.1.11 Rest of Middle East
13.5.1.11.1 Rest of Middle East Pharmacovigilance Market By Product Life Cycle
13.5.1.11.2 Rest of Middle East Pharmacovigilance Market By Service Provider Outlook
13.5.1.11.3 Rest of Middle East Pharmacovigilance Market By Process Flow Outlook
13.5.1.11.4 Rest of Middle East Pharmacovigilance Market By Therapeutic Outlook
13.5.1.11.5 Rest of Middle East Pharmacovigilance Market By End Use Outlook
13.5.2 Africa
13.5.2.1 Africa Pharmacovigilance Market By Country
13.5.2.2 Africa Pharmacovigilance Market By Product Life Cycle
13.5.2.3 Africa Pharmacovigilance Market By Service Provider Outlook
13.5.2.4 Africa Pharmacovigilance Market By Process Flow Outlook
13.5.2.5 Africa Pharmacovigilance Market By Therapeutic Outlook
13.5.2.6 Africa Pharmacovigilance Market By End Use Outlook
13.5.2.7 Nigeria
13.5.2.7.1 Nigeria Pharmacovigilance Market By Product Life Cycle
13.5.2.7.2 Nigeria Pharmacovigilance Market By Service Provider Outlook
13.5.2.7.3 Nigeria Pharmacovigilance Market By Process Flow Outlook
13.5.2.7.4 Nigeria Pharmacovigilance Market By Therapeutic Outlook
13.5.2.7.5 Nigeria Pharmacovigilance Market By End Use Outlook
13.5.2.8 South Africa
13.5.2.8.1 South Africa Pharmacovigilance Market By Product Life Cycle
13.5.2.8.2 South Africa Pharmacovigilance Market By Service Provider Outlook
13.5.2.8.3 South Africa Pharmacovigilance Market By Process Flow Outlook
13.5.2.8.4 South Africa Pharmacovigilance Market By Therapeutic Outlook
13.5.2.8.5 South Africa Pharmacovigilance Market By End Use Outlook
13.5.2.9 Rest of Africa
13.5.2.9.1 Rest of Africa Pharmacovigilance Market By Product Life Cycle
13.5.2.9.2 Rest of Africa Pharmacovigilance Market By Service Provider Outlook
13.5.2.9.3 Rest of Africa Pharmacovigilance Market By Process Flow Outlook
13.5.2.9.4 Rest of Africa Pharmacovigilance Market By Therapeutic Outlook
13.5.2.9.5 Rest of Africa Pharmacovigilance Market By End Use Outlook
13.6 Latin America
13.6.1 Latin America Pharmacovigilance Market By Country
13.6.2 Latin America Pharmacovigilance Market By Product Life Cycle
13.6.3 Latin America Pharmacovigilance Market By Service Provider Outlook
13.6.4 Latin America Pharmacovigilance Market By Process Flow Outlook
13.6.5 Latin America Pharmacovigilance Market By Therapeutic Outlook
13.6.6 Latin America Pharmacovigilance Market By End Use Outlook
13.6.7 Brazil
13.6.7.1 Brazil Pharmacovigilance Market By Product Life Cycle
13.6.7.2 Brazil Africa Pharmacovigilance Market By Service Provider Outlook
13.6.7.3Brazil Pharmacovigilance Market By Process Flow Outlook
13.6.7.4 Brazil Pharmacovigilance Market By Therapeutic Outlook
13.6.7.5 Brazil Pharmacovigilance Market By End Use Outlook
13.6.8 Argentina
13.6.8.1 Argentina Pharmacovigilance Market By Product Life Cycle
13.6.8.2 Argentina Pharmacovigilance Market By Service Provider Outlook
13.6.8.3 Argentina Pharmacovigilance Market By Process Flow Outlook
13.6.8.4 Argentina Pharmacovigilance Market By Therapeutic Outlook
13.6.8.5 Argentina Pharmacovigilance Market By End Use Outlook
13.6.9 Colombia
13.6.9.1 Colombia Pharmacovigilance Market By Product Life Cycle
13.6.9.2 Colombia Pharmacovigilance Market By Service Provider Outlook
13.6.9.3 Colombia Pharmacovigilance Market By Process Flow Outlook
13.6.9.4 Colombia Pharmacovigilance Market By Therapeutic Outlook
13.6.9.5 Colombia Pharmacovigilance Market By End Use Outlook
13.6.10 Rest of Latin America
13.6.10.1 Rest of Latin America Pharmacovigilance Market By Product Life Cycle
13.6.10.2 Rest of Latin America Pharmacovigilance Market By Service Provider Outlook
13.6.10.3 Rest of Latin America Pharmacovigilance Market By Process Flow Outlook
13.6.10.4 Rest of Latin America Pharmacovigilance Market By Therapeutic Outlook
13.6.10.5 Rest of Latin America Pharmacovigilance Market By End Use Outlook
14. Company Profile
14.1 Accenture
14.1.1 Company Overview
14.1.2 Financials
14.1.3 Product/Services Offered
14.1.4 SWOT Analysis
14.1.5 The SNS View
14.2 IQVIA
14.2.1 Company Overview
14.2.2 Financials
14.2.3 Product/Services Offered
14.2.4 SWOT Analysis
14.2.5 The SNS View
14.3 Cognizant
14.3.1 Company Overview
14.3.2 Financials
14.3.3 Product/Services Offered
14.3.4 SWOT Analysis
14.3.5 The SNS View
14.4 IBM Corp
14.4.1 Company Overview
14.4.2 Financials
14.4.3 Product/Services Offered
14.4.4 SWOT Analysis
14.4.5 The SNS View
14.5 Wipro Ltd
14.5.1 Company Overview
14.5.2 Financials
14.5.3 Product/Services Offered
14.5.4 SWOT Analysis
14.5.5 The SNS View
14.6 BioClinica Inc
14.6.1 Company Overview
14.6.2 Financials
14.6.3 Product/Services Offered
14.6.4 SWOT Analysis
14.6.5 The SNS View
14.7 Capgemini
14.7.1 Company Overview
14.7.2 Financials
14.7.3 Product/Services Offered
14.7.4 SWOT Analysis
14.7.5 The SNS View
14.8 ArisGlobal
14.8.1 Company Overview
14.8.2 Financials
14.8.3 Product/Services Offered
14.8.4 SWOT Analysis
14.8.5 The SNS View
14.9 ITClinical
14.9.1 Company Overview
14.9.2 Financials
14.9.3 Product/Services Offered
14.9.4 SWOT Analysis
14.9.5 The SNS View
14.10 ClinChoice
14.10.1 Company Overview
14.10.2 Financials
14.10.3 Product/Services Offered
14.10.4 SWOT Analysis
14.10.5 The SNS View
14.11 United BioSource LLC
14.11.1 Company Overview
14.11.2 Financials
14.11.3 Product/Services Offered
14.11.4 SWOT Analysis
14.11.5 The SNS View
14.12 Parexel International Corp.
14.12.1 Company Overview
14.12.2 Financials
14.12.3 Product/Services Offered
14.12.4 SWOT Analysis
14.12.5 The SNS View
14.13 TAKE Solutions Ltd.
14.13.1 Company Overview
14.13.2 Financials
14.13.3 Product/Services Offered
14.13.4 SWOT Analysis
14.13.5 The SNS View
14.14 TAKE Solutions Ltd.
14.14.1 Company Overview
14.14.2 Financials
14.14.3 Product/Services Offered
14.14.4 SWOT Analysis
14.14.5 The SNS View
14.15 ICON plc
14.15.1 Company Overview
14.15.2 Financials
14.15.3 Product/Services Offered
14.15.4 SWOT Analysis
14.15.5 The SNS View
14.16 ICON plc
14.16.1 Company Overview
14.16.2 Financials
14.16.3 Product/Services Offered
14.16.4 SWOT Analysis
14.16.5 The SNS View
14.17 Laboratory Corporation of America Holdings
14.17.1 Company Overview
14.17.2 Financials
14.17.3 Product/Services Offered
14.17.4 SWOT Analysis
14.17.5 The SNS View
15. Competitive Landscape
15.1 Competitive Bench marking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. USE Cases and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The AI in Pathology Market size was valued at USD 1050.18 million in 2023 and is expected to grow to USD 1915.21 million by 2031 and grow at a CAGR Of 7.8% over the forecast period of 2024-2031.
The Patient Access Solutions Market Size was valued at USD 1.84 billion in 2022, and is expected to reach USD 3.60 billion by 2030, and grow at a CAGR of 8.7% over the forecast period 2023-2030.
In 2022, The Smart Contact Lenses Market size amounted to USD 445.28 Million & is estimated to reach USD 6098.80 Million by 2030 and increase at a compound annual growth rate of 38.7% between 2023 and 2030.
The Medical Carts Market was estimated at USD 2.64 billion in 2022 and is poised to reach at 7.87 billion in 2030 anticipated to expand at a compound annual growth rate approx. CAGR of 16.88% for the forecast period of 2023-2030.
The Surgical Retractors Market Size was valued at USD 2.03 billion in 2023, and is expected to reach USD 3.54 billion by 2031, and grow at a CAGR of 6.8% over the forecast period 2024-2031.
The Blockchain Technology in Healthcare Market Size was valued at USD 3.3 billion in 2023 and is expected to reach USD 214.44 billion by 2031, and grow at a CAGR of 68.5% over the forecast period 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
